ROTAVAC-5D is low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination, Bharat Biotech said.
Krishna Ella, Chairman and Managing Director of Bharat Biotech.
Bharat Biotech on August 2 said its Rotavirus vaccine ROTAVAC 5D was awarded World Health Organization (WHO) prequalification.
ROTAVAC 5D is used for the prevention of rotavirus infection, which is prevalent in infants and young children.
The WHO Prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO.
“It is a validation of the global quality and safety standards required for pediatric vaccines. WHO prequalification of ROTAVAC 5D will fast-track global access to this life saving vaccine,” Bharat Biotech said.
ROTAVAC 5D is the new formulation of original rotavirus vaccine ROTAVAC developed by Bharat Biotech. The rotavirus vaccine formulation can be administered without a buffer or pH stabilising agent used in vaccine formulations.
ROTAVAC-5D is low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination, Bharat Biotech said.
Bharat Biotech has so far supplied more than 250 million doses of ROTAVAC vaccine.
“ROTAVAC and ROTAVAC 5D are projects conceived, innovated, and executed in India; in collaboration with Indian and global partners,” said Suchitra Ella, Joint Managing Director, Bharat Biotech.
Rotavirus is the leading cause of severe diarrhea among children less than five years of age around the world, resulting in more than 200,000 deaths and 2 million hospitalizations worldwide. Vaccinations are an important part of global public health efforts to meet the Sustainable Developmental Goals of UNDP.
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
